ALMS (Alumis) Other Stockholders Equity : $0.00 Mil (As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Alumis Other Stockholders Equity?

Alumis's Other Stockholders Equity for the quarter that ended in Mar. 2025 was $0.00 Mil.

Alumis's quarterly Other Stockholders Equity increased from Sep. 2024 ($-0.00 Mil) to Dec. 2024 ($0.00 Mil) but then stayed the same from Dec. 2024 ($0.00 Mil) to Mar. 2025 ($0.00 Mil).

Alumis Other Stockholders Equity Historical Data

The historical data trend for Alumis's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alumis Other Stockholders Equity Chart

Alumis Annual Data

Trend

Dec22

Dec23

Dec24

Other Stockholders Equity

Alumis Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Other Stockholders Equity	Get a 7-Day Free Trial					-	-	-	-	-

Alumis Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

Alumis Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Alumis's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Alumis Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alumis Inc (NAS:ALMS) » Definitions » Other Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

280 East Grand Avenue, South San Francisco, CA, USA, 94080

Website

https://www.alumis.com

Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.